RE:RE:RE:Perspectives, perspectives, perspectives ... Hi bencro;
Thank you for your effort to respond to my questions of how to most effectively raise capital to advance Theralase near term agenda.
Based on your suggestion that we need to dilute by 25 million shares, and I would suggest most likely 25 million attached warrants, we would be adding a probable 50 million shares, roughly 30% more shares to our current fully diluted 167 million shares.
Your are suggesting that we would raise roughly $12-$18 million for the immediate future, and we would most certainly need to raise considerably more funds to carry us to the point of commercialization. We lack the experience and marketing depth to reach sustainable revenues and profits, not to mention the high cash cost of marketing.
I could be wrong, but I would think that a joint venture with the right deep pocketed partner for NMIBC, would yield us vastly more funds, add experienced marketing muscle, and visibility, without the risk of open ended future dilutive measures.
If I am right, than our dilution ends near here. A joint venture should secure enough funds to easily advance us through 5-6 indications. By joint venturing NMIBC we gave up 20% of a portfolio of our first 5-6 indications but will receive plenty of working capital, a royalty stream, and the profits from selling the necessary supplies, lasers, tools, and appliances.
The joint venture solution is not open ended and will get us to the goal line.
As always bencro, thanks again for your thoughtful analysis.
made2last